Skip to main content
SWOG logo

User account menu

  • Log in

Main navigation

  • About
    • History & Impact
    • Mission & Values
    • Leadership
    • Support SWOG
    • Join SWOG
    • Policies & Procedures
    • Careers
    • Contact Us
  • The SWOG Network
    • How We Work
    • Our Staff
    • Our Advocates
    • Our Partners
  • News & Events
    • News
    • SWOG Meetings
    • For Press
  • Clinical Trials
    • Biospecimen Submission
    • Biospecimen Access
    • Data Requests
    • Clinical Trials Search
    • Clinical Research Resources
    • Frequently Asked Questions
    • Publications
    • Institutions
    • Quality Assurance & Audits
    • Serious Adverse Events
    • Training Resources
    • ORP (CRA) Workbench
    • Protocol Workbench
  • Workbenches
    • ORP (CRA) Workbench
    • Protocol Workbench
    • VA Workbench
  • For Patients
    • Patient & Advocate Voices
    • Trials Open to Patients
    • About SWOG Cancer Trials
    • Joining a Trial

Breadcrumb

  1. SWOG
  2. News & Events
  3. News
  4. News

News

SIGN UP FOR EMAIL UPDATES
ASH 2020
Press Release
Dec 7, 2020

AL Amyloidosis Drug Results Shared at #ASH20

New Front Line
The Front Line
Dec 4, 2020

Taking It All Online

SABCS 2020
Press Release
Dec 2, 2020

SWOG Hits SABCS with High-Impact Research

New Front Line
The Front Line
Nov 20, 2020

COVID Forcing Virtual Spring Meeting

New Front Line
The Front Line
Nov 13, 2020

Our Continuing Commitment to Veterans

Dr. Michael Wagner
Press Release
Nov 13, 2020

Rare Angiosarcomas Respond to Immumotherapy

VA Integration Support Program Grants
Press Release
Nov 10, 2020

Grants Help VA Centers Enroll Vets to Trials

New Front Line
The Front Line
Nov 6, 2020

New Data Era Dawns at SWOG

New Front Line
The Front Line
Oct 30, 2020

New Online Learning Management System Ready

  • Previous page ‹
  • First page 1
  • …
  • Page31
  • Current page32
  • Page33
  • …
  • Last page 65
  • Next page ›
SWOG logo

Footer: Social Links

  • LinkedIn
  • Twitter
  • YouTube
Copyright © 2025

Footer

  • Disclaimer